Thalidomide enhances cyclophosphamide and dexamethasone-mediated cytotoxicity towards cultured chronic lymphocytic leukaemia cells

Numerous chemotherapeutic regimens exist for the treatment of symptomatic or progressive chronic lymphocytic leukaemia (CLL). However, once the disease becomes refractory to nucleoside-based therapy the prognosis is poor. In this study we investigated the cytotoxicity of thalidomide in combination w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology reports 2010-11, Vol.24 (5), p.1315-1321
Hauptverfasser:	POINTON, Joanna C, EAGLE, Gina, BAILEY, James, EVANS, Paul, ALLSUP, David, GREENMAN, John
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - pharmacology Biological and medical sciences Cohort Studies Cyclophosphamide - administration & dosage Cyclophosphamide - pharmacology Dexamethasone - administration & dosage Dexamethasone - pharmacology Drug Synergism Female Hematologic and hematopoietic diseases Humans Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Thalidomide - administration & dosage Thalidomide - pharmacology Tumor Cells, Cultured Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!